Associated Papers
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
41152984 (PubMed )
Supplement: 13073_2025_1564_MOESM2_ESM.xlsx › Table_S5
Hit discovery of potential CDK8 inhibitors and analysis of amino acid mutations for cancer therapy through computer-aided drug discovery.
Aghahasani R et al.
Bmc Chemistry, 2024
Identification and characterization of the mediator kinase-dependent myometrial stem cell phosphoproteome.
Barron L et al.
F&s Science, 2021
Loss of Cyclin C or CDK8 provides ATR inhibitor resistance by suppressing transcription-associated replication stress.
Lloyd RL et al.
Nucleic Acids Research, 2021
De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder.
Calpena E et al.
American Journal of Human Genetics, 2019
A molecular dynamics investigation of CDK8/CycC and ligand binding: conformational flexibility and implication in drug discovery.
Cholko T et al.
Journal of Computer-aided Molecular Design, 2018
A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease.
Dale T et al.
Nature Chemical Biology, 2015
MED12 mutations link intellectual disability syndromes with dysregulated GLI3-dependent Sonic Hedgehog signaling.
Zhou H et al.
Proceedings of the National Academy of Sciences of the United States of America, 2012
The structure of CDK8/CycC implicates specificity in the CDK/cyclin family and reveals interaction with a deep pocket binder.
Schneider EV et al.
Journal of Molecular Biology, 2011
The histone variant macroH2A suppresses melanoma progression through regulation of CDK8.
Kapoor A et al.
Nature, 2010
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.
Firestein R et al.
Nature, 2008
TFIIH is negatively regulated by cdk8-containing mediator complexes.
Akoulitchev S et al.
Nature, 2000
Select a paper to view details